LS9, Inc., the Renewable Petroleum Company™, Adds Charles Cooney to Board of Directors

LS9

LS9, Inc., the Renewable Petroleum Company™, Adds Charles Cooney to Board of Directors

August 8, 2007

SAN CARLOS, Calif., Aug. 8 /PRNewswire/ -- LS9, Inc., the Renewable Petroleum Company™, today announced that the company has appointed Charles L. Cooney to its Board of Directors. Dr. Cooney's extensive manufacturing and scale-up expertise, along with his business-building and corporate governance experience, will significantly contribute to the rapid commercialization of LS9 DesignerBiofuels™ products.

Dr. Cooney, Professor of Chemical and Biochemical Engineering at the Massachusetts Institute of Technology, is a Director of Genzyme, Chair of its Compensation Committee, and a member of the Nominating/Governance Committee. Since 1983, he has helped shepherd Genzyme in the transition from a start-up company to over $3 billion in annual revenues and a public market capitalization of approximately $17 billion. In addition, Dr. Cooney recently completed a six-year tenure on the BP Technical Advisory Council.

Dr. Cooney's research interests span a range of topics in biochemical engineering and manufacturing strategy in the pharmaceutical, biotech, and biofuels industries, as well as bioprocess design, operation, and control. He has published over 300 research papers, over 30 patents, and co-authored or edited five books including the recently published Development of Sustainable Bioprocesses: Modeling and Assessment, Wiley Press 2006. As founding faculty director of the Deshpande Center, Dr. Cooney is interested in the process of stimulating technological innovation and translating innovation into new company creation.

"We are extremely pleased to welcome Dr. Cooney as an independent director and gain his valuable insight," said Noubar Afeyan, Co-founder and Chairman of LS9 and Managing Partner of Flagship Ventures. "I have known Charlie for many years and deeply respect his extensive experience at the interfaces of engineering and business and of engineering and biology."

"Dr. Cooney's unique combination of insight and experiences from both the petroleum and biotechnology industries further strengthens our team and ability to strategically implement our commercialization plans," said Robert Walsh, LS9 President and fellow Board member. "Dr. Cooney will be a real asset to LS9 and we will immediately benefit from his active involvement with our company."

About LS9

LS9, Inc., the Renewable Petroleum Company™, is a privately-held biotechnology company and the pioneer in the commercial development of hydrocarbon biofuels. LS9 is pursuing industrial applications of synthetic biology to produce proprietary hydrocarbon biofuels that are compatible with existing fuel distribution and consumer infrastructure. LS9's patent-pending DesignerBiofuels™ products are custom engineered in the lab to address immediate market needs for clean energy alternatives to petroleum. The company was founded in 2005 by leading scientists along with specialized venture capital firms Flagship Ventures and Khosla Ventures. LS9 is headquartered in San Carlos, California, in the heart of Silicon Valley. http://www.ls9.com/.